Sun Pharma Advanced Research Company Ltd. announced the completion of enrolment of 506 patients in a global, randomized, double- blind, placebo-controlled Phase 2 study in patients with early Parkinson's disease evaluating the safety and efficacy of Abl tyrosine kinase inhibition using K0706 (PROSEEK). PROSEEK is global, randomized, double-blind, placebo-controlled Phase 2 study in patients with early Parkinson's disease evaluating the safety and efficacy of Abl tyrosine kinase inhibition using K0706/SCC-138. The primary endpoint is the change from baseline to week 40 in the score of the MDS-UPDRS Part III (Movement Disorder Society - Unified Parkinson's Disease Rating Scale).

The key secondary endpoints include: Change from baseline to Week 40 in the sum of the MDS-UPDRS Parts II and III total scores. Time from baseline to initiation of symptomatic medication. Change in health-related quality of life as measured by the European quality of life questionnaire.

Change in Clinician global impression of severity About Vodobatinib (SCC-138/K0706): Vodobatinib is a potential first-in-class, highly selective and brain penetrating c-Abl inhibitor. Vodobatinib is being evaluated under multiple clinical trials in patients with Parkinson's disease, Dementia with Lewy Body and Chronic Myelogenous Leukemia.